glp-1 and hypertension Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control Obesity treatment and hypertension management

Orforglipron: First Oral GLP-1 Without Refrigeration Eli Lillys Orforglipron is a once-daily GLP-1 receptor agonist currently in advanced clinical trials

The cagrilintide and semaglutide doses were escalated every 4 weeks, with final dose achieved at 16 weeks

The drug will still likely have the intestinal side effects common to GLP-1 drugs, but those symptoms may be more manageable with less frequent treatments

Long feedback loops with easily recognizable structural impacts on the body

Commonly reported side effects include: Nausea or queasiness Reduced appetite Digestive changes Dry mouth Metallic or altered taste sensations These effects vary by individual, dosage, and duration of treatment